Patent granted for NT-proBNP in the U.S.

05 Dec 2022 11:09 CET

Moss, 5 December 2022

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, is pleased to announce that it has been granted a patent in the U.S. for
its product candidate NT-proBNP.

NT-proBNP is a non-invasive biomarker for the diagnosis of congestive heart
failure (CHF). An aging population and lifestyle choices increase the cost
burden in healthcare systems and thereby drive demand for NT-proBNP testing.

Gentian’s assay, which is currently under development, aims to be the first
turbidimetric IVD test for NT-proBNP supporting improved laboratory throughput
and productivity. Additionally, Gentian aims to contribute to easier
standardisation of test results.

“The issued patent is an important milestone towards the development of
NT-proBNP as it de-risks the product’s commercial potential. We remain
optimistic that we can overcome the remaining challenges in product
development,” commented Hilja Ibert, CEO of Gentian Diagnostics.

In its Q3 2022 report, Gentian gave an update on the progress made on NT-proBNP
currently in the optimisation phase. A working prototype was established in the
quarter and additional testing is ongoing. Further, the establishment of the
reference method at the first trial site has been accomplished supporting the
process of calibrating the immunoassay towards commercially available products.

The patent for NT-proBNP is issued by the U.S. Patent and Trademark Office.

For further information, please contact:
Hilja Ibert, CEO
hilja.ibert@gentian.no
+47 919 05 242

Njaal Kind, CFO and COO
njaal.kind@gentian.no
+47 919 06 525


About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures
high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lie
within immunochemistry, specifically infections, inflammations, kidney failures
and congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is based in
Moss, Norway, serving the global and veterinary diagnostics markets through
sales and representative offices in Sweden, USA and China. For more information,
please visit www.gentian.com.

More information:
Access the news on Oslo Bors NewsWeb site